Abstract
BackgroundThe updated BANFF 2013 criteria has enabled a more standardized and complete serologic and histopathologic diagnosis of chronic active antibody mediated rejection (cAMR). Little data exists on the outcomes of cAMR since the initiation of this updated criteria. Methods123 consecutive patients with biopsy proven cAMR (BANFF 2013) between 2006 and 2012 were identified. ResultsPatients identified with cAMR were followed for a median of 9.5 (2.7–20.3) years after transplant and 4.3 (0–8.8) years after cAMR. Ninety-four (76%) recipients lost their grafts with a median survival of 1.9years after diagnosis with cAMR. Mean C4d and allograft glomerulopathy scores were 2.6±0.7 and 2.2±0.8, respectively. 53.2% had class II DSA, 32.2% had both class I and II, and 14.5% had class I DSA only. Chronicity score >8 (HR 2.9, 95% CI 1–8.4, p=0.05), DSA >2500 MFI (HR 2.8, 95% CI 1.1–6.8, p=0.03), Scr >3mg/dL (HR 3.2, 95% CI 1.6–6.3, p=0.001) and UPC >1g/g (HR 2.5, 95% CI 1.4–4.5, p=0.003) were associated with a higher risk of graft loss. ConclusionscAMR was associated with poor graft survival after diagnosis. Improved therapies and earlier detection strategies are likely needed to improve outcomes of cAMR in kidney transplant recipients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
